All enrolled individuals who obtained no less than just one dose of zosuquidar or placebo during induction were monitored with the event of adverse activities (439 patients, 219 on zosuquidar and 210 on placebo). The commonest adverse gatherings have been linked to the duration of prolonged and substantial myelosuppression as https://murrayi544seo6.wikipublicist.com/user